TrialJapanese journal of clinical oncology2022

Subgroup analysis of Japanese patients in a phase III randomized, controlled study of neoadjuvant atezolizumab or placebo, combined with nab-paclitaxel and anthracycline-based chemotherapy in early triple-negative breast cancer (IMpassion031).

Shigehira Saji et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.